首页 Atossa Genetics(usATOS)-基本信息

Atossa Genetics(usATOS)-基本信息

日报更新时间:07-02 06:53

周报更新时间:01-23 11:54

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

英文名称:Atossa Genetics


简介:Atossa Genetics Inc.于2009年4月30日在特拉华州注册成立,是一家医疗保健公司,致力于乳腺癌的预防,通过诊断医疗设备和实验室开发的测试推广前体乳腺癌的检测,并通过研究、开发、最终推广前期病变和导管原位癌的治疗


电话:1-800-3513902


最新量化综合结论
百科信息
  • 相关网站
  • 员工交易记录
  • 持股信息
  • 领导人信息

交易日期 交易人 职位 类型 交易份额 价格
2017-11-14 Guse (Kyle) General Counsel Buy 1400 0.34
2017-11-14 Guse (Kyle) General Counsel Buy 8600 0.34

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
BlackRock Fund Advisors 54 -- -- -- 2019-07-31
Dimensional Fund Advisors LP 7600 0.08% -1349 -15.07% 2019-07-31
Lake Street Risk Retention Group Inc 26200 0.29% 26200 -- 2019-03-31
Bridgeway Capital Management, Inc 26200 0.29% 26200 -- 2019-03-31
Virtu Financial LLC 36310 0.40% -33593 -48.06% 2019-03-31
Geode Capital Management, LLC 47372 0.52% 15834 50.21% 2019-03-31
Vanguard Group Inc 69489 0.76% 572 0.83% 2019-03-31
Fidelity Management & Research Company 80384 0.88% -- -- 2019-07-31
Ahrens Investment Partners LLC 100000 1.10% 100000 -- 2019-03-31
Barclays PLC 7234 0.08% -25150 -77.66% 2019-03-31
BARCLAYS CAPITAL Inc 7184 0.08% -25200 -77.82% 2019-03-31
Northern Trust Investments Inc 2578 0.03% -- -- 2019-07-31
Pnc Bank, National Association 66 -- -- -- 2019-03-31
PNC Financial Services Group Inc 66 -- -- -- 2019-03-31
Mosaic Family Wealth, LLC 107 -- -- -- 2019-03-31
Parallax Volatility Advisers, LLC 209 -- 209 -- 2019-03-31
BlackRock Asset Management Canada Ltd 216 -- -- -- 2019-07-31
BlackRock Inc 671 0.01% -- -- 2019-03-31
Morgan Stanley - Brokerage Accounts 2383 0.03% 1396 141.44% 2019-03-31
Morgan Stanley Smith Barney LLC 2383 0.03% 2383 -- 2019-03-31
Sabby Management LLC 502448 5.51% 37409 8.04% 2018-12-31
JANE STREET GROUP, LLC 22339 0.24% -1253 -5.31% 2018-12-31
TWO SIGMA SECURITIES, LLC 12474 0.14% 12474 -- 2018-12-31
Panagora Asset Management Inc 11255 0.12% -2361 -17.34% 2018-12-31
Macquarie Funds Management HK Ltd. 5700 0.06% 5700 -- 2018-12-31
UBS Group AG 4755 0.08% 4755 -- 2018-12-31
Macquarie Group Ltd 5700 0.10% 5700 -- 2018-12-31
Bank of America Corporation 167 -- 167 -- 2018-09-30
Wells Fargo & Co 83 -- -- -- 2018-09-30
Advisor Group, Inc. 416 0.01% -- -- 2018-09-30
Fifth Third Bancorp 41 -- -- -- 2018-09-30
TRUEWEALTH LLC 45 -- -- -- 2018-12-31
Invesco Capital Management LLC 1103 0.02% -- -- 2019-01-31
FMR Inc 27 -- 27 -- 2018-09-30
Anson Funds Management LP 108977 1.93% 108977 -- 2018-06-30
Vanguard 465 0.01% -2 -0.43% 2018-11-30
Susquehanna International Group, LLP 24162 0.43% 24162 -- 2018-06-30
Susquehanna Financial Group, LLLP 24162 0.43% 24162 -- 2018-06-30
UBS Securities LLC 9128 0.16% 9128 -- 2018-06-30
Deutsche Bank AG 1107 0.02% 1107 -- 2018-06-30
BlackRock Institutional Trust Company NA 617 0.01% 617 -- 2018-06-30
Wells Fargo Advisors, LLC 83 -- -- -- 2018-09-30
Guggenheim Funds Investment Advisors LLC 1260 0.02% -- -- 2018-09-14
Intracoastal Capital LLC 164907 0.52% 164907 -- 2018-04-23
Merrill Lynch & Co Inc 1308 -- 1308 -- 2017-12-31
Iroquois Capital Management, LLC 118144 0.37% -2181856 -94.86% 2017-12-31
Good Life Advisors, LLC 20333 0.06% -- -- 2017-12-31
Renaissance Technologies Corp 10824 0.03% -324687 -96.77% 2017-12-31
Royal Bank Of Canada 2 -- 2 -- 2017-09-30
Morgan Stanley & Co Inc 178 -- 178 -- 2017-09-30
Empery Asset Management, LP 2300000 16.40% 2300000 -- 2017-10-26
KCG AMERICAS LLC 53735 0.54% 3672 7.33% 2017-06-30
Hudson Bay Capital Management LP 95396 0.98% 26492 38.45% 2017-06-30
Steven C. Quay, M.D., Ph.D. 4746858 3.00% 8544344 0.20% 1999-11-30
Shu-Chih Chen, Ph.D. 4268315 3.00% 7682967 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Invesco Wilshire Micro-Cap ETF -- -- -1103 -100.00% 2019-02-22
Bridgeway Ultra Small Company Fund 26200 0.29% 26200 -- 2019-03-31
Fidelity 9613 0.11% -- -- 2019-06-30
DFA US Small Cap Portfolio 5251 0.06% 2351 81.07% 2019-05-31
NT Ext Equity Market Index Fund - L 2578 0.03% -- -- 2019-06-30
DFA Tax Managed US Small Cap Portfolio 2349 0.03% -- -- 2019-06-30
iShares Core S&P US Total Market ETF 54 -- -- -- 2019-05-30
iShares Core Balanced ETF Portfolio 54 -- -- -- 2019-05-30
iShares Core MSCI AllCntry Wld exCan ETF 54 -- -- -- 2019-05-30
iShares Core Growth ETF Portfolio 54 -- -- -- 2019-05-30
iShares Core S&P Total US Stock Mkt ETF 54 -- -- -- 2019-07-30
DFA US Micro Cap Portfolio -- -- -3700 -100.00% 2018-10-31
Vanguard Extended Market Index Fund 120689 1.32% -- -- 2019-06-30
The Vanguard Total Stock Market Index 465 0.01% -2 -0.43% 2017-12-31
iShares Core S&P Total US Stock Mkt 54 -- -- -- 2018-09-12
Wilshire Micro-Cap ETF 1260 0.02% -- -- 2018-09-14
DFA US Micro Cap I 3700 0.08% -- -- 2018-07-31
Fidelity Spartan 13949 0.29% -- -- 2018-07-31
Vanguard Extended Market Idx Inv 33864 0.69% -33864 -50.00% 2018-07-31
Fidelity Spartan® Extended Mkt Indx Fd 80935 0.30% -- -- 2015-09-30
iShares Micro-Cap 60656 0.20% -- -- 2015-11-16
The Vanguard - Total Stk Mkt Idx Trust. CF 7000 -- -- -- 2015-09-30
Fidelity® NASDAQ Composite Index® Fund 4348 -- -- -- 2015-09-30
AXA/Lord Abbett Micro Cap Portfolio 3682 -- -- -- 2015-09-30
Fidelity Spartan® Total Market Idx Fund 789 -- -- -- 2015-09-30
Vanguard Total Stock Mkt Idx 295017 1.00% -- -- 2015-09-30

Steven C. Quay Founder of Atossa Genetics, Inc., Sonus Pharmaceuticals, Inc., Nycomed Salutar, Inc. and Salutar, Inc., Steven C. Quay is an entrepreneur and businessperson who has been at the helm of 5 different companies and holds the position of Chairman, President & Chief Executive Officer of Atossa Genetics, Inc. and Chairman & President at National Reference Laboratory For Breast Health, Inc. Dr. Quay is also Member of Society for Laboratory Automation & Screening, Member of American Society for Investigative Pathology, Member of Association for Molecular Pathology and Member of Association for Pathology Informatics, Inc. In his past career Dr. Quay was Chairman & Chief Scientific Officer at Silverleaf Resorts, Inc., Chairman, President & Chief Executive Officer of Atossa Healthcare, Inc. and President & Chief Executive Officer for Sonus Pharmaceuticals, Inc. Steven C. Quay received an undergraduate degree from Western Michigan University and a doctorate from the University of Michigan Medical School.
Richard I. Steinhart Currently, Richard I. Steinhart is Chief Financial Officer & Vice President at BioXcel Therapeutics, Inc. He is also on the board of Atossa Genetics, Inc. and Actinium Pharmaceuticals, Inc. Mr. Steinhart previously was Managing Director at SAE Ventures, Chief Financial Officer of Remedy Pharmaceuticals, Inc., Secretary & Treasurer at STRATA Skin Sciences, Inc., Chief Financial Officer & General Partner at CW Group, Inc., Chief Financial Officer & Vice President for Emisphere Technologies, Inc. and Managing Director at Forest Street Capital, LLC. He received an MBA and an undergraduate degree from Pace University.
Gregory L. Weaver Presently, Gregory L. Weaver holds the position of Chief Financial & Accounting Officer of Eloxx Pharmaceuticals, Inc. He is also on the board of Atossa Genetics, Inc. Mr. Weaver previously was Chief Financial Officer at Poniard Pharmaceuticals, Inc., CFO, Secretary, Treasurer & Senior Vice President at Fibrocell Science, Inc., Chief Financial Officer for Verity Solutions Group, Chief Financial Officer & Senior Vice President at Celsion Corp., Chief Financial Officer for Eloxx Pharmaceuticals, Inc. and Chief Financial Officer for Sevion Therapeutics, Inc. (a subsidiary of Eloxx Pharmaceuticals, Inc.), Global Chief Financial Officer & Executive VP at Oryzon Genomics SA, Chief Financial Officer for ILEX Oncology, Inc., Chief Financial Officer, Secretary & VP at MDRNA, Inc., Chief Financial Officer & Senior Vice President at Sirna Therapeutics, Inc., Chief Financial Officer for Oncology, Inc., Chief Financial Officer at ProMetic Life Sciences, Inc. and Chief Financial Officer at Prism Technologies, Inc. Mr. Weaver received an MBA from Boston College and an undergraduate degree from Trinity University.
H. Lawrence Remmel H. Lawrence Remmel is on the board of Atossa Genetics, Inc. and CytoDel LLC and Partner at Pryor Cashman LLP and Member of New York State Bar Association. He previously occupied the position of Associate of Carter, Ledyard & Milburn LLP and Associate of Reboul, MacMurray, Hewitt, Maynard & Kristol. H. Lawrence Remmel received an undergraduate degree from Princeton University and a graduate degree from Washington & Lee University School of Law.
Kyle Guse Presently, Kyle Guse is CFO, Secretary & Chief Accounting Officer at Atossa Genetics, Inc. In his past career Mr. Guse was Partner at Baker Botts LLP, Partner at McDermott Will & Emery LLP, Partner at Heller Ehrman LLP, Accountant for Deloitte & Touche LLP and Member of California State Bar Association. Mr. Guse received a graduate degree from The Santa Clara University School of Law and an MBA and an undergraduate degree from California State University-Sacramento.
Shu Chih Chen Shu Chih Chen founded Atossa Genetics, Inc. and SC2Q Consulting Co. She is on the board of Atossa Genetics, Inc. Dr. Chen previously was President for SC2Q Consulting Co., President for Ensisheim Partners LLC and Associate Professor at National Yang Ming University. Dr. Chen received a doctorate from Michigan State University and an undergraduate degree from National Yang Ming University.
Stephen J. Galli Stephen J. Galli is on the board of Atossa Genetics, Inc. and Professor at Stanford University School of Medicine. Dr. Galli previously occupied the position of President for American Society for Investigative Pathology and President at Collegium Internationale Allergologicum. He received an undergraduate degree from Harvard College and a doctorate from Harvard Medical School.
Janet Rose Rea Presently, Janet Rose Rea is VP-Regulatory Affairs, Quality & Clinical Affairs at Atossa Genetics, Inc. In her past career Ms. Rea was Assistant Clinical Professor at the University of Washington. She received an undergraduate degree and a graduate degree from the University of Washington.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐